Competing interests
Heart Failure, heart failure, NDD
PCT, HEART FAILURE, HEART FAILURE, HEART, EDWARDS
is registered as an investor in a PCT regarding the use of metabolic regulators for COVID. The author has a patent on the use of PPAR agonists to treat COVID. The author has no other competing interests to declare.No competing interests declared.No competing interests declared.has received personal honoraria for statistical consultation from Recipharm, and personal honoraria for manuscript writing from both Sharper Srl and Fidia Pharmaceuticals. The author has no other competing interests to declare.is President of Fondazione (totally supported by family). The author has no other competing interests to declare.received funding from National Institutes of Health (1R01HL157108-01A1,1R01AG074989-01) . The author has no other competing interests to declare.has received consulting honoraria from Sanifit, Bristol Myers Squibb, Merck, Edwards Lifesciences, Bayer, JNJ, Fukuda-Denshi, NGM Bio, Mayo institute of technology and the University of Delaware, and research grants from the National Institutes of Health, Abbott, Microsoft, Fukuda-Denshi and Bristol Myers Squibb. He has received compensation from the American Heart Association and the American College of Cardiology for editorial roles, and visiting speaker honoraria from Washington University, Emory University, University of Utah, the Japanese Association for Cardiovascular Nursing and the Korean Society of Cardiology. The author is named as inventor in a University of Pennsylvania patent for the use of inorganic nitrates/nitrites for the treatment of Heart Failure and Preserved Ejection Fraction and for the use of biomarkers in heart failure with preserved ejection fraction. The author has participated on the Advisory board for Bristol-Myers Squibb Data safety monitoring board for studies by the University of Delaware and UT Southwestern, and is Vice President of North American Artery Society. The author has received research device loans from Atcor Medical, Fukuda-Denshi, Unex, Uscom, NDD Medical Technologies, Microsoft, and MicroVision Medical. The author has no other competing interests to declare.is affiliated with BioStats Statistical Consulting Ltd where they work as a Biostatistician. The authors has received payment for statistical work for the manuscript and consulting fees from Tissue Dynamics Ltd. The author has no other competing interests to declare.has received consulting honoraria from Sanofi, Roche and Neopharm, and lectures honoraria from Roche . He is the chairmen of the Israel Association for the study of the liver. The author has no other competing interests to declare.is registered as an investor in a PCT regarding the use of metabolic regulators for COVID and has a patent on the use of PPAR agonists to treat COVID. The author has no other competing interests to declare.